MX336958B - Metodos y composiciones para modular la hemostasia. - Google Patents

Metodos y composiciones para modular la hemostasia.

Info

Publication number
MX336958B
MX336958B MX2012006836A MX2012006836A MX336958B MX 336958 B MX336958 B MX 336958B MX 2012006836 A MX2012006836 A MX 2012006836A MX 2012006836 A MX2012006836 A MX 2012006836A MX 336958 B MX336958 B MX 336958B
Authority
MX
Mexico
Prior art keywords
methods
hemostasia
modulate
compositions
variants
Prior art date
Application number
MX2012006836A
Other languages
English (en)
Inventor
Rodney M Camire
Original Assignee
Philadelphia Children Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philadelphia Children Hospital filed Critical Philadelphia Children Hospital
Publication of MX336958B publication Critical patent/MX336958B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una variante del Factor Xa que modula la hemostasia que comprende al menos una mutación por substitución en los aminoácidos 41-179 y 235-488 de SEQ ID NO: 1, en donde el Asp en la posición 418 (posición 194 en el sistema de numeración de quimiotripsina) se sustituye con Asn o Glu.
MX2012006836A 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia. MX336958B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73668005P 2005-11-15 2005-11-15
PCT/US2006/060927 WO2007059513A2 (en) 2005-11-15 2006-11-15 Compositions and methods for modulating hemostasis

Publications (1)

Publication Number Publication Date
MX336958B true MX336958B (es) 2016-02-05

Family

ID=38049397

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2012006836A MX336958B (es) 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia.
MX2008006313A MX2008006313A (es) 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia.
MX2012006837A MX337059B (es) 2005-11-15 2008-05-15 Metodos y composiciones para modular la hemostasia.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2008006313A MX2008006313A (es) 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia.
MX2012006837A MX337059B (es) 2005-11-15 2008-05-15 Metodos y composiciones para modular la hemostasia.

Country Status (26)

Country Link
US (4) US8383386B2 (es)
EP (4) EP1948690B1 (es)
JP (4) JP5823088B2 (es)
KR (4) KR101574042B1 (es)
CN (1) CN101356192B (es)
AU (1) AU2006315175B2 (es)
BR (1) BRPI0618654B1 (es)
CA (2) CA2971971A1 (es)
CR (1) CR9956A (es)
DK (1) DK1948690T3 (es)
EC (1) ECSP088452A (es)
ES (2) ES2549929T3 (es)
GT (1) GT200800065A (es)
HK (2) HK1128699A1 (es)
IL (1) IL191310A (es)
MX (3) MX336958B (es)
MY (1) MY162181A (es)
NO (3) NO345177B1 (es)
NZ (1) NZ568108A (es)
PL (1) PL1948690T3 (es)
PT (1) PT1948690E (es)
RU (2) RU2008123398A (es)
SI (1) SI1948690T1 (es)
SV (1) SV2008002906A (es)
WO (1) WO2007059513A2 (es)
ZA (1) ZA200804026B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3078743T (lt) 2007-09-28 2020-09-25 Portola Pharmaceuticals, Inc. Antikūnai xa veiksnio inhibitoriams ir jų naudojimo būdai
JP5709316B2 (ja) 2008-11-14 2015-04-30 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子阻害剤のための解毒剤および血液凝固剤と組み合わせて該解毒剤を使用する方法
EP2414517B1 (en) 2009-03-30 2016-09-21 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
CA2767858C (en) 2009-07-15 2019-02-12 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
EP2624859B1 (en) 2010-10-06 2017-03-01 Medimmune Limited Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy
WO2013049804A1 (en) * 2011-09-30 2013-04-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
WO2014018120A1 (en) 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
US20150343034A1 (en) 2013-01-31 2015-12-03 Pfizer Inc. Compositions and methods for counteracting factor xa inhibition
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
MY173548A (en) 2013-09-24 2020-02-04 Pfizer Fxa variant compositions
US20160235824A1 (en) * 2013-11-01 2016-08-18 The Children's Hospital Philadelphia Compositions and Methods for Increasing the Half-Life of Factor XA
EP3096779B1 (en) * 2014-01-24 2019-12-18 Pfizer Inc Compositions and methods for treating intracerebral hemorrhage
RS60706B1 (sr) 2014-05-26 2020-09-30 Academisch Ziekenhuis Leiden Prohemostatski proteini za lečenje krvarenja
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
CN109789181A (zh) 2016-07-27 2019-05-21 费城儿童医院 用于调节因子ix功能的组合物和方法
WO2023118150A1 (en) 2021-12-22 2023-06-29 Royal College Of Surgeons In Ireland A conjugate for use in localising a molecule to the vascular endothelium.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
CA2160583A1 (en) 1993-04-16 1994-10-27 Stanley A. Plotkin Recombinant cytomegalovirus vaccine
WO1995005864A1 (en) 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
JP3961019B2 (ja) 1995-02-28 2007-08-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 遺伝子転移媒介の血管形成療法
AU2319497A (en) 1996-03-07 1997-09-22 Regents Of The University Of California, The Helper-free, totally defective adenovirus for gene therapy
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT410216B (de) * 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) * 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
CN102325880B (zh) * 2008-12-19 2014-10-01 国家健康与医学研究院 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途

Also Published As

Publication number Publication date
PT1948690E (pt) 2014-09-08
KR101827569B1 (ko) 2018-02-09
KR20080078664A (ko) 2008-08-27
US20140120155A1 (en) 2014-05-01
CA2629491C (en) 2019-05-07
ZA200804026B (en) 2009-10-28
KR20140005383A (ko) 2014-01-14
MY162181A (en) 2017-05-31
ES2549929T3 (es) 2015-11-03
US20180251745A1 (en) 2018-09-06
JP2014073127A (ja) 2014-04-24
BRPI0618654A2 (pt) 2011-09-06
HK1128699A1 (en) 2009-11-06
RU2570547C2 (ru) 2015-12-10
WO2007059513A3 (en) 2007-11-29
NO20200671A1 (no) 2008-07-30
US20160362673A1 (en) 2016-12-15
BRPI0618654A8 (pt) 2019-01-15
US8383386B2 (en) 2013-02-26
KR20140115374A (ko) 2014-09-30
NZ568108A (en) 2011-09-30
AU2006315175B2 (en) 2013-02-07
JP5957167B2 (ja) 2016-07-27
EP2431389A1 (en) 2012-03-21
EP2431390B1 (en) 2015-08-12
IL191310A (en) 2015-06-30
CN101356192B (zh) 2013-09-11
ECSP088452A (es) 2008-07-30
JP2009515559A (ja) 2009-04-16
RU2008123398A (ru) 2009-12-27
EP1948690B1 (en) 2014-06-11
KR20160029135A (ko) 2016-03-14
KR101600158B1 (ko) 2016-03-08
NO345177B1 (no) 2020-10-26
SV2008002906A (es) 2008-10-22
KR101574042B1 (ko) 2015-12-03
JP2018033459A (ja) 2018-03-08
MX2008006313A (es) 2008-11-06
RU2011130932A (ru) 2013-01-27
CR9956A (es) 2008-08-21
JP2016005464A (ja) 2016-01-14
CN101356192A (zh) 2009-01-28
NO20200670A1 (no) 2008-07-30
US20090175931A1 (en) 2009-07-09
PL1948690T3 (pl) 2014-11-28
MX337059B (es) 2016-02-09
GT200800065A (es) 2008-11-03
WO2007059513A2 (en) 2007-05-24
DK1948690T3 (da) 2014-09-01
CA2629491A1 (en) 2007-05-24
EP2431390A1 (en) 2012-03-21
EP2423224B1 (en) 2015-08-12
JP6236194B2 (ja) 2017-11-22
ES2496567T3 (es) 2014-09-19
JP6571735B2 (ja) 2019-09-04
BRPI0618654B1 (pt) 2021-10-19
JP5823088B2 (ja) 2015-11-25
US9896676B2 (en) 2018-02-20
HK1165444A1 (zh) 2012-10-05
SI1948690T1 (sl) 2014-09-30
NO20082182L (no) 2008-07-30
EP2423224A1 (en) 2012-02-29
US9410137B2 (en) 2016-08-09
EP1948690A2 (en) 2008-07-30
EP1948690A4 (en) 2009-06-17
AU2006315175A1 (en) 2007-05-24
CA2971971A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
MX336958B (es) Metodos y composiciones para modular la hemostasia.
CY1117833T1 (el) Νεες συνθεσεις και μεθοδοι για την αγωγη του καρκινου
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
CR10213A (es) Moduladores de la proteína quinasa aurora
NO20092637L (no) Fremgangsmater for behandling
CY2014030I1 (el) Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
EA200700537A1 (ru) Триазолофталазины
EA201070519A1 (ru) Соединения тропана
CR11373A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA
CY2014011I1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
EA200802008A1 (ru) Фармацевтические композиции
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA201100037A1 (ru) Органические соединения
CR10094A (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
SV2009003434A (es) Inhibicion de arni de expresion de alfa-enac
CL2008000873A1 (es) Compuestos derivados de pirrolidin amidas; composicion farmaceutica que comprende dichos compuestos; y su uso para tratar trombosis.
UY29853A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas-
BRPI0813000A2 (pt) Composições terapêuticas e uso das mesmas
UY31484A1 (es) Piperidinas heteroaril-sustituidas
BRPI0720211A2 (pt) Derivado de indanona, composição, e, uso de uma composição
EA200870515A1 (ru) Моноциклические гетероарильные соединения
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
HK1142608A1 (en) 5-pyridinone substituted indazoles and pharmaceutical compositions thereof 5-
PA8630801A1 (es) Nuevos imidazoles